No Picture
News

DURECT to Host Key Opinion Leader Call on DUR-928 Phase 2a Alcoholic Hepatitis Study Results

Call will feature data from DURECT’s late-breaking oral presentation at the 2019 Liver Meeting®

CUPERTINO, Calif., Nov. 6, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will host a key opinion leader (KOL) conference … […]

No Picture
News

Evofem Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Company on Track for Amphora NDA Resubmission to the U.S. FDAPhase 2b AMPREVENCE Trial Results Anticipated in Q4 2019Management to Host Conference Call Thursday, November 7, 2019 at 11:00 a.m. EST

SAN DIEGO, Nov. 6, 2019 /PRNewswire/ — Evofem Biosci… […]

No Picture
News

Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Conference call scheduled for 8:30 a.m. ET today- IND Application Filed for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH- Clinical Development of VK0214 for X-ALD Expected to Begin 1H20- Balance Sheet Remains Strong with Approximately $290 Million… […]

No Picture
News

Viking Therapeutics to Report Financial Results for Third Quarter 2019 on November 5, 2019

Conference Call Scheduled for Tuesday, November 5 at 8:30 a.m. Eastern Time

SAN DIEGO, Oct. 31, 2019 /PRNewswire/ — Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel t… […]

No Picture
News

Evofem Biosciences to Report Third Quarter 2019 Results and Provide Corporate Update on November 7, 2019

— Conference Call Scheduled for 11:00 a.m. EST —

SAN DIEGO, Oct. 24, 2019 /PRNewswire/ — Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company’s financial results and business highlights for the th… […]